Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
AssigneeNovartis AG
InventorsStefan Ewert, Andrew Green, Alexander Wolfgang Koch
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to reversal agents, which specifically bind to anti-Factor XI and/or anti-Factor XIa antibodies (e.g., NOV1401), and reverse one or more anticoagulant effects of the anti-Factor XI and/or anti-Factor XIa antibodies (e.g., NOV1401), as well as to methods of use thereof, such as methods for reversing anticoagulant effects of such anti-Factor XI and/or anti-Factor XIa antibodies (e.g., NOV1401), and to related methods for managing bleeding or bleeding risks.
Claims19
An antibody or antigen-binding fragment thereof that specifically binds to an anti-FXI/FXIa antibody wherein the antibody or antigen-binding fragment comprises a heavy chain variable region (VH) comprising complementarity determining regions HCDR1, HCDR2, and HCDR3, and a light chain variable region (VL) comprising complementarity determining regions LCDR1, LCDR2, and LCDR3, wherein:
- (a) the HCDR1 comprises an amino acid sequence selected from SEQ ID NO:
- 51, 54, 55 and 57, the HCDR2 comprises an amino acid sequence selected from SEQ ID NO:
- 121, 122, and 123, the HCDR3 comprises an amino acid sequence selected from SEQ ID NO:
- 53 and 59, the LCDR1 comprises an amino acid sequence selected from SEQ ID NO:
- 64, 67 and 70, the LCDR2 comprises an amino acid sequence selected from SEQ ID NO:
- 65 and 68, and the LCDR3 comprises an amino acid sequence selected from SEQ ID NO:
- 125 and 126;
- (b) the HCDR1 comprises an amino acid sequence selected from SEQ ID NO:
- 51, 54, 55 and 57, the HCDR2 comprises an amino acid sequence selected from SEQ ID NO:
- 105, 106 and 107, the HCDR3 comprises an amino acid sequence selected from SEQ ID NO:
- 53 and 59, the LCDR1 comprises an amino acid sequence selected from SEQ ID NO:
- 64, 67 and 70, the LCDR2 comprises an amino acid sequence selected from SEQ ID NO:
- 65 and 68, and the LCDR3 comprises an amino acid sequence selected from SEQ ID NO:
- 66 and 69;
- (c) the HCDR1 comprises an amino acid sequence selected from SEQ ID NO:
- 51, 54, 55 and 57, the HCDR2 comprises an amino acid sequence selected from SEQ ID NO:
- 75, 76 and 77, the HCDR3 comprises an amino acid sequence selected from SEQ ID NO:
- 53 and 59, the LCDR1 comprises an amino acid sequence selected from SEQ ID NO:
- 64, 67 and 70, the LCDR2 comprises an amino acid sequence selected from SEQ ID NO:
- 65 and 68, and the LCDR3 comprises an amino acid sequence selected from SEQ ID NO:
- 94 and 95;
- (d) the HCDR1 comprises an amino acid sequence selected from SEQ ID NO:
- 51, 54, 55 and 57, the HCDR2 comprises an amino acid sequence selected from SEQ ID NO:
- 52, 56 and 58, the HCDR3 comprises an amino acid sequence selected from SEQ ID NO:
- 53 and 59, the LCDR1 comprises an amino acid sequence selected from SEQ ID NO:
- 64, 67 and 70, the LCDR2 comprises an amino acid sequence selected from SEQ ID NO:
- 65 and 68, and the LCDR3 comprises an amino acid sequence selected from SEQ ID NO:
- 94 and 95;
- (e) the HCDR1 comprises an amino acid sequence selected from SEQ ID NO:
- 51, 54, 55 and 57, the HCDR2 comprises an amino acid sequence selected from SEQ ID NO:
- 105, 106 and 107, the HCDR3 comprises an amino acid sequence selected from SEQ ID NO:
- 53 and 59, the LCDR1 comprises an amino acid sequence selected from SEQ ID NO:
- 64, 67 and 70, the LCDR2 comprises an amino acid sequence selected from SEQ ID NO:
- 65 and 68, and the LCDR3 comprises an amino acid sequence selected from SEQ ID NO:
- 94 and 95;
- or
- (f) the HCDR1 comprises an amino acid sequence selected from SEQ ID NO:
- 51, 54, 55 and 57, the HCDR2 comprises an amino acid sequence selected from SEQ ID NO:
- 75, 76 and 77, the HCDR3 comprises an amino acid sequence selected from SEQ ID NO:
- 53 and 59, the LCDR1 comprises an amino acid sequence selected from SEQ ID NO:
- 64, 67 and 70, the LCDR2 comprises an amino acid sequence selected from SEQ ID NO:
- 65 and 68, and the LCDR3 comprises an amino acid sequence selected from SEQ ID NO:
- 66 and 69.
Dependencies are inferred from the claim text.